The sharp rise in global diabetes incidence in recent years has put increasing pressure on pharmaceuticals to accelerate the research and development of new therapeutics for the disease.In recent years, new hypoglycemic drugs, such as GLP-1RA (glucagon-like peptide-1 receptor agonist) and SGLT2i (sodium-glucose cotransporter 2 inhibitor), have rapidly began to occupy an expanding space in the global market.

KingMylab offers a complete testing catalog of biological and clinical indicators of diabetes, and holds a rich project management experience in diabetes related clinical trials. We are committed to establishing a scientific and rigorous quality management system and a leading and comprehensive technology platform to power new drug development and create a healthier future for diabetic patients. Since 2010, we have supported more than 100 clinical research projects on diabetes, and have tested more than 100,000 samples. And with the recent advances in new classes of therapeutics, central laboratory service and support are more important than ever before, as multi-dimensional and multi-plaform biomarkers and indicators are key for evaluating drug efficacy and safety.